PD23: Prostate Cancer: Advanced (including drug therapy) II
Sunday, May 17, 2026 3:30 PM to 5:30 PM · 2 hr. (America/New_York)
206
Poster and Podium Sessions
Oncology: Prostate
Information
Continuing Medical Education
CME
Sunday, May 17
PD23-01: Utility of PROSTest, a novel blood-based mRNA assay, for predicting outcome to 177LuPSMA radioligand therapy
Sunday, May 17, 2026 3:30 PM to 3:38 PM
206
Mark Kidd · Wren Labs
PD23-02: Prostate-specific antigen endpoints in the phase 3 PSMAddition study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive (PSMA+) metastatic hormone-sensitive prostate cancer (mHSPC)
Sunday, May 17, 2026 3:38 PM to 3:46 PM
206
Fred Saad · University of Montreal Hospital Center
PD23-03: Clinical and Molecular Predictors of Response to Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer
Sunday, May 17, 2026 3:46 PM to 3:54 PM
206
Ruth Pe Benito
PD23-04: Delayed Survival Benefit of Enzalutamide Plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: A Reconstructed Individual Patient Data Analysis of the PEACE-3 Trial
Sunday, May 17, 2026 3:54 PM to 4:02 PM
206
Soichiro Yoshida
PD23-05: Duration of treatment suspension among all randomized patients in EMBARK
Sunday, May 17, 2026 4:02 PM to 4:10 PM
206
Neal Shore · Carolina Urologic Research Center
PD23-06: Radiographic Progression-Free Survival as a Meaningful Endpoint in Metastatic Castration-Resistant Prostate Cancer (mCRPC): The TALAPRO-2 Randomized Clinical Trial
Sunday, May 17, 2026 4:10 PM to 4:18 PM
206
Neeraj Agarwal · Huntsman Cancer Institute, University of Utah
PD23-07: A prospective cohort study comparing the efficacy of neoadjuvant abiraterone +/- docetaxel followed by radical prostatectomy with up-front radical prostatectomy in locally advanced prostate cancer
Sunday, May 17, 2026 4:18 PM to 4:26 PM
206
Xuan Wang
PD23-08: Results of a prospective, single-center phase-II study on modern androgen deprivation therapy followed by cytoreductive radical prostatectomy in men with de novo metastatic hormone-sensitive prostate cancer (mHSPC)
Sunday, May 17, 2026 4:26 PM to 4:34 PM
206
Axel Heidenreich · University of Cologne, Dept of Urology
PD23-09: Effect of cytoreductive radical prostatectomy combined with hormonal therapy in patients with oligometastatic prostate cancer:a multicentered prospective non-randomized control study
Sunday, May 17, 2026 4:34 PM to 4:42 PM
206
Lei Xu
PD23-10: Cardiovascular Consequences of Androgen Deprivation Therapy in Prostate Cancer Patients: A Short-Term Prospective Analysis
Sunday, May 17, 2026 4:42 PM to 4:50 PM
206
Deerush Kannan Sakthivel · Miami Cancer Institute, Baptist Health South Florida
PD23-11: Serum testosterone level and Bone Scan Index at diagnosis predict progression of high-volume metastatic castration-sensitive prostate cancer treated with novel androgen receptor signal inhibitors doublet therapy
Sunday, May 17, 2026 4:50 PM to 4:58 PM
206
Yutaka Horiguchi · Department of Urology, Edogawa Hospital
PD23-12: An artificial intelligence algorithm characterizes the deterioration of body composition from systemic therapy for patients with advanced prostate cancer
Sunday, May 17, 2026 4:58 PM to 5:06 PM
206
Chloe Shi
PD23-13: Radical Prostatectomy in STAMPEDE-Defined High-Risk Prostate Cancer: Long-Term Oncologic and Perioperative Outcomes from a Large Single-Center Cohort
Sunday, May 17, 2026 5:06 PM to 5:14 PM
206
Simone Scuderi · Unit of Urology - Division of Oncology - Gianfranco Soldera Prostate Cancer Lab - IRCCS San Raffaele Scientific Institute - Vita-Salute San Raffaele University
PD23-14: Treatment patterns and survival in veterans with hormone-sensitive metastatic prostate cancer imaged with PSMA PET/CT
Sunday, May 17, 2026 5:14 PM to 5:22 PM
206
Harris Allen
PD23-15: Safety of rucaparib vs docetaxel or second-generation androgen receptor pathway inhibitor therapy for patients with metastatic castration-resistant prostate cancer and a BRCA mutation in TRITON3
Sunday, May 17, 2026 5:22 PM to 5:30 PM
206
Alan Bryce
